Marty Makary has left his position as FDA Commissioner following a turbulent tenure marked by internal conflict at the agency, according to RealClearPolitics. His departure is the latest in a series of leadership exits across HHS under the current administration.

FDA Commissioner Marty Makary stepped down, with President Trump announcing on Truth Social that Kyle Diamantas, the agency's top food regulator, will take over, according to The Hill. Said Trump, speaking to reporters: Makary had been "having some difficulty" in the role.

FDA Commissioner Marty Makary resigned from the agency, according to The Hill. Makary drew criticism from multiple directions during his tenure, including from the pharmaceutical and biotech industries as well as anti-abortion groups.

FDA Commissioner Marty Makary resigned and will be replaced in an acting capacity by Kyle Diamantas, according to Bloomberg Politics. President Trump confirmed the departure.

President Trump removed FDA Commissioner Marty Makary from his post, according to two sources familiar with the matter cited by NBC News. NBC's Berkeley Lovelace Jr. reported that Trump had grown frustrated with Makary's performance and had previously considered firing him before the decision was made.

Marty Makary resigned as FDA commissioner, with one source telling CBS News that his departure stems from a dispute over flavored e-cigarettes — specifically that Makary had refused to approve fruit-flavored vaping products from Glas Inc. but was pressured by the administration to do so before the FDA approved them on May 6, according to CBS News. Said President Trump on the South Lawn: "Marty's a terrific guy, but he's going to go on and he's going to lead a good life. He was having some difficulty." Kyle Diamantas is expected to serve as acting commissioner.

FDA Commissioner Marty Makary resigned after weeks of pressure on his tenure as the nation's top food, drug, tobacco, and medical device regulator, according to the New York Times. The agency's top food official will step in as acting commissioner.

Justice Samuel Alito extended a freeze on restrictions for mifepristone mail-order prescribing, keeping the Biden-era teleprescribing policy in place through 5 p.m. Thursday, according to Axios. The extension came in response to requests from drugmakers Danco Laboratories and GenBioPro, who asked the Court to restore mail and telehealth access to the pill while litigation continues.

President Trump has approved a plan to fire FDA Commissioner Marty Makary, according to CBS News, citing two sources. The Wall Street Journal, which first reported the decision, noted that Trump had pressured Makary to approve fruit-flavored e-cigarettes — which Makary had been refusing — and that White House advisers told the president Makary was blocking the administration's vaping agenda.

The New York Times reported May 8 that Trump plans to fire FDA Commissioner Marty Makary, just months into his tenure. The proximate cause: Makary made enemies inside the administration by taking positions on vaping, the abortion pill, and drug rejections that crossed the wrong people.

The strategic read is straightforward. Makary was a MAHA ally — he got the job because of it. But MAHA is RFK Jr.'s operation, and when a commissioner applies actual regulatory judgment rather than ideological compliance, the White House treats that as insubordination. Vaping has industry money behind it. The abortion pill has politics behind it. Makary tried to run a functional agency. That's not what this FDA slot is for.

Firing a Senate-confirmed commissioner for making science-based calls is executive pressure on an independent regulatory function — the same pattern playing out across every agency where process still occasionally produces inconvenient results.

The White House is preparing to replace FDA Commissioner Marty Makary, according to the Washington Post, as the agency faces mounting internal turmoil under the broader restructuring driven by Robert F. Kennedy Jr.'s Health and Human Services portfolio.

The play here is transparent: Makary was a Kennedy-adjacent pick meant to legitimize RFK Jr.'s vaccine skepticism inside a credentialed institution. If he's being pushed out now, it means he either wasn't compliant enough or became a liability when the political cost of FDA dysfunction started showing up somewhere that mattered — drug approvals, Wall Street, Republican senators with pharma money.

Watch who replaces him. A more ideologically committed successor signals the administration is doubling down on dismantling FDA's independent scientific posture. A technocrat signals retreat. The nominee is the tell.

Trump plans to fire FDA Commissioner Marty Makary following months of turmoil inside the agency, Bloomberg Politics reported Thursday, citing a person familiar with the matter.

The strategic read here is simple: Makary was brought in as a reform-friendly outsider, but disorder at FDA has become a liability the White House can no longer absorb. Firing him doesn't solve the underlying chaos — it signals that the chaos is the point. A rudderless FDA means slower drug approvals, weaker pandemic-prep capacity, and an agency too destabilized to push back on anything.

Who benefits: anyone who wants pharmaceutical and food-safety oversight neutered without the political cost of formally abolishing it. Robert F. Kennedy Jr.'s HHS sits directly above FDA. Watch who gets nominated next — that name will tell you everything about the actual operational agenda.

Bloomberg Politics reports that Robert F. Kennedy Jr. and a network of personal injury lawyers are pressing a legal campaign against Merck's Gardasil vaccine, accusing the company of 'disease mongering' to inflate sales — a charge that runs directly against decades of mainstream medical consensus on the vaccine's safety and efficacy.

The strategic read: this isn't primarily a tort story. It's an executive-branch play. Kennedy now controls public health infrastructure. Personal injury litigation that once faced an uphill regulatory environment can now proceed in a climate shaped by the very official who built the case against the product.

Who benefits: the plaintiff's bar funding this effort, and an HHS leadership that has spent years treating vaccine approval as a political grievance rather than a public-health process. The constitutional concern is downstream: when a Cabinet officer's ideological priors reshape the regulatory record, every future safety determination at FDA is compromised before it begins.

A political appointee inside HHS intervened to block approval of Sanofi's Tzield — a drug already on the market for type 1 diabetes — according to STAT News reporting on the agency's D.C. Diagnosis newsletter. The interference adds to a documented pattern of political pressure on FDA's scientific review process under the current administration.

The operative detail: this isn't a novel compound under scrutiny for safety unknowns. Tzield has an existing approval trail. A political layer inserting itself into that process isn't regulatory caution — it's a tell. Someone is running a play, and it isn't about protecting patients.

Who benefits from an unpredictable FDA? Anyone who wants the approval process to be a negotiating lever rather than a scientific one. Once that norm breaks, every pending approval becomes a pressure point. That's not a bug in this operation — it's the architecture.

Per Rachel Bade, FDA Commissioner Marty Makary is the next senior official on the way out as Trump finishes his pre-midterm housecleaning. Makary is a Trump appointee. The criterion isn't competence or even ideology — it's personal loyalty under stress. Cabinet-level government has been replaced with a permanent audition for the principal's approval, and the agencies that protect public health are not exempt.